Methods for determining odds of cardiac arrest amongst hospitalized COVID-19 patients in New York City given Azithromycin, Hydroxychloroquine, or a combination
- Sample selection
- Data collection
- Data/variables of interest
- Statistical analysis
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Hazard ratio for time to in-hospital mortality amongst hospitalized COVID-19 patients in New York City were not significantly different for those given Azithromycin, Hydroxychloroquine, or a combination
Proportion of abnormal ECG findings in hospitalized COVID-19 patients in New York City were higher amongst those who received Azithromycin+Hydroxychloroquine and Hydroxychloroquine
Learn After
Data collection for evaluating outcomes in hospitalized COVID-19 patients in New York City given Azithromycin, Hydrochloroquine, or a combination
Sample selection for evaluating outcomes in hospitalized COVID-19 patients in New York City given Azithromycin, Hydroxychloroquine, or a combination
Data/variables of interest for evaluating outcomes in hospitalized COVID-19 patients in New York City given Azithromycin, Hydroxychloroquine, or a combination
Learn After
Data collection for evaluating outcomes in hospitalized COVID-19 patients in New York City given Azithromycin, Hydrochloroquine, or a combination
Sample selection for evaluating outcomes in hospitalized COVID-19 patients in New York City given Azithromycin, Hydroxychloroquine, or a combination
Data/variables of interest for evaluating outcomes in hospitalized COVID-19 patients in New York City given Azithromycin, Hydroxychloroquine, or a combination
Related
Hazard ratio for time to in-hospital mortality amongst hospitalized COVID-19 patients in New York City were not significantly different for those given Azithromycin, Hydroxychloroquine, or a combination
Proportion of abnormal ECG findings in hospitalized COVID-19 patients in New York City were higher amongst those who received Azithromycin+Hydroxychloroquine and Hydroxychloroquine